Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene

REFERENCES

• Meyerhardt , J. A. and Mayer , R. J. 2005 . Systemic therapy for colorectal cancer . N. Engl. J. Med. , 352 : 476 – 487 .
   PubMed Web of Science ®Google Scholar
• Twelves , C. , Wong , A. , Nowacki , M. P. , Abt , M. Burris , H. III . 2005 . Capecitabine as adjuvant treatment for stage III colon cancer . N. Engl. J. Med. , 352 : 2696 – 2704 .
   PubMed Web of Science ®Google Scholar
• Mattison , L. K. , Soong , R. and Diasio , R. B. 2002 . Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics . Pharmacogenomics , 3 : 485 – 492 .
   PubMed Web of Science ®Google Scholar
• van Kuilenburg , A. B. P. 2004 . Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil . Eur. J. Cancer , 40 : 939 – 950 .
   PubMed Web of Science ®Google Scholar
• van Kuilenburg , A. B. P. , Haasjes , J. , Richel , D. J. , Zoetekouw , L. van Lenthe , H. 2000 . Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene . Clin. Cancer Res. , 6 : 4705 – 4712 .
   PubMed Web of Science ®Google Scholar
• Milano , G. A. , Etienne , M. C. , Pierrefite , V. , Barberi-Heyob , M. , Deporte-Fety , R. and Renée , N. 1999 . Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity . Br. J. Cancer , 79 : 627 – 630 .
   PubMed Web of Science ®Google Scholar
• Morel , A. , Boisdron-Celle , M. , Fey , L. , Soulie , P. Craipeau , M. C. 2006 . Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance . Mol. Cancer Ther. , 5 : 2895 – 2904 .
   PubMed Web of Science ®Google Scholar
• Johnson , M. R. , Wang , K. and Diasio , R. B. 2002 . Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype . Clin. Cancer Res. , 8 : 768 – 774 .
   PubMed Web of Science ®Google Scholar
• Raida , M. , Schwabe , W. , Häusler , P. , van Kuilenburg , A. B. P. van Gennip , A. H. 2001 . Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls . Clin. Cancer Res. , 7 : 2832 – 2839 .
   PubMed Web of Science ®Google Scholar
• van Kuilenburg , A. B. P. , Vreken , P. , Abeling , N. G. G. M. , Bakker , H. D. Meinsma , J. R. 1999 . Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency . Hum. Genet. , 104 : 1 – 9 .
   PubMed Web of Science ®Google Scholar
• Boisdron-Celle , M. , Remaud , G. , Traore , S. , Poirier , A. L. Gamelin , L. 2007 . 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency . Cancer Lett. , 249 : 271 – 282 .
   PubMed Web of Science ®Google Scholar
• Di Paolo , A. , Danesi , R. , Falcone , A. , Cionini , L. Vannozzi , F. 2001 . Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients . Ann. Oncol. , 12 : 1301 – 1306 .
   PubMed Web of Science ®Google Scholar
• Gamelin , E. and Boisdron-Celle , M. 1999 . Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer–status of the art . Crit Rev. Oncol. Hematol. , 30 : 71 – 79 .
   PubMed Web of Science ®Google Scholar
• Maring , J. G. , van Kuilenburg , A. B. P. , Haasjes , J. , Piersma , H. Groen , H. J. M. 2002 . Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene . Br. J. Cancer , 86 : 1028 – 1033 .
   PubMed Web of Science ®Google Scholar
• Gusella , M. , Crepaldi , G. , Barile , C. , Bononi , A. Menon , D. 2006 . Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer . Ann. Oncol. , 17 : 1656 – 1660 .
   PubMed Web of Science ®Google Scholar
• Codacci-Pisanelli , G. , Pinedo , H. M. , Lankelma , J. , Van Groeningen , C. J. van Kuilenburg , A. B. P. 2005 . Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity . J. Chemother. , 17 : 315 – 320 .
   PubMed Web of Science ®Google Scholar
• Schalhorn , A. , Peyerl , G. and Denecke , H. 1988 . Pharmacokinetics of 5-fluorouracil during isolated liver perfusion . Regional Cancer Treatment , 1 : 21 – 27 .
   Google Scholar
• Busse , D. , Busch , F. W. , Bohnenstengel , F. , Eichelbaum , M. Fischer , P. 1979 . Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism . J. Clin. Oncol. , 15 : 1885 – 1896 .
   Google Scholar
• Rothenberg , M. L. , Oza , A. M. , Bigelow , R. H. , Berlin , J. D. Marshall , J. L. 2003 . Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial . J. Clin. Oncol. , 21 : 2059 – 2069 .
   PubMed Web of Science ®Google Scholar
• Diasio , R. B. , Beavers , T. L. and Carpenter , J. T. 1988 . Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity . J. Clin. Invest. , 81 : 47 – 51 .
   PubMed Web of Science ®Google Scholar
• Johnson , M. R. and Diasio , R. B. 2001 . Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil . Adv. Enzyme Regul. , 41 : 151 – 157 .
   PubMedGoogle Scholar
• Mattison , L. K. , Ezzeldin , H. , Carpenter , M. , Modak , A. , Johnson , M. R. and Diasio , R. B. 2004 . Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test . Clin. Cancer Res. , 10 : 2652 – 2658 .
   PubMed Web of Science ®Google Scholar
• Wei , X. , McLeod , H. L. , McMurrough , J. and Gonzalez , F. J. 1996 . Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity . J. Clin. Invest. , 98 : 610 – 615 .
   PubMed Web of Science ®Google Scholar
• Vreken , P. , van Kuilenburg , A. B. P. , Meinsma , J. R. , Smit , G. P. A. Bakker , H. D. 1996 . A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency . J. Inherit. Metab. Dis. , 19 : 645 – 654 .
   PubMed Web of Science ®Google Scholar
• Bocci , G. , Barbara , C. , Vannozzi , F. , Di , P. A. , Melosi , A. Barsanti , G. 2006 . A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity . Clin. Pharmacol. Ther. , 80 : 384 – 395 .
   PubMed Web of Science ®Google Scholar
• van Kuilenburg , A. B. P. , Meinsma , J. R. , Zoetekouw , L. and van Gennip , A. H. 2002 . Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g > a mutation . Int. J. Cancer , 101 : 253 – 258 .
   PubMed Web of Science ®Google Scholar